BHST — BIOHARVEST SCIENCES INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723464 ·
Last close
$1.22
Market Cap
$27.65M
52W High
$7.20
52W Low
$0.91
ADV30
28,340
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 7,867,000 | 4,235,000 | -3,042,000 | -3,324,000 | — | — | — |
| Jun 2026 | 8,837,000 | 5,082,000 | -2,507,000 | -3,715,000 | 44,569,000 | 15,211,000 | 24,805,000 |
| Mar 2026 | 8,507,000 | 5,037,000 | -1,834,000 | -2,641,000 | 45,558,000 | 19,167,000 | 22,535,000 |
| Dec 2025 | 9,066,000 | 5,225,000 | -1,121,000 | -2,204,000 | 47,665,000 | 23,025,000 | 22,217,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,513,000
Investing CF
$-3,254,000
Financing CF
$23,164,000
CapEx
$-2,240,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-113,909,000
Inventory
$5,779,000
Receivables
$4,178,000
ST Investments
$1,012,000
EBIT TTM
$-8,932,000
Pretax Income TTM
$-10,976,000
Interest Exp TTM
$2,044,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,477,000
EBITDA
$-5,804,000
Free Cash Flow
$-11,845,250
Enterprise Value
$41,407,508
Total Cash
$16,223,000
Total Debt
$15,695,000
Shares Out
22,667,842
Trailing EPS
$-0.51
Book Value
$0.87
ROE
-142.5%
ROA
-11.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 34,508,000 | -5,575,000 | -11,135,000 | 47,665,000 | 22,217,000 | 25,448,000 | -7,226,000 |
| Dec 2024 | 25,188,000 | -6,989,000 | -12,913,000 | 25,001,000 | 23,671,000 | 1,330,000 | -6,684,000 |
| Dec 2023 | 12,672,000 | -9,966,000 | -12,564,000 | 15,002,000 | 29,855,000 | -14,853,000 | -8,522,000 |
| Dec 2022 | 5,498,000 | -10,612,000 | -11,236,000 | 9,393,000 | 15,322,000 | -5,929,000 | -9,241,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MCUJF | MEDICURE INC | $27.45M | $2.63 | — |
| PYRGF | PyroGenesis Canada Inc. | $28.34M | $0.13 | — |
| SCYX | SCYNEXIS INC | $28.37M | $2.85 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $26.89M | $0.64 | — |
| PMN | ProMIS Neurosciences Inc. | $28.88M | $3.21 | — |
News headlines (Yahoo Finance, 1h cache)
BioHarvest Sciences Inc. Common Stock Q3 2026 Earnings Call Summary
2026-11-12 18:15 · Yahoo
BioHarvest (BHST) Q3 2026 Earnings Call Transcript
2026-11-12 16:31 · Yahoo
BioHarvest Sciences posts US$7.9M Q3 revenue as fragrance supply deal sets up 2027 growth
2026-11-12 13:42 · Yahoo
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 11:10 · Yahoo
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 11:00 · Yahoo
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-10-29 12:00 · Yahoo
BioHarvest takes second plant-cell asset to commercial readiness
2026-10-13 13:06 · Yahoo
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
2026-10-13 11:00 · Yahoo
BioHarvest says its platform can produce target sweetener in Tate & Lyle program
2026-10-08 13:37 · Yahoo
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
2026-10-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.